Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Cash from Investing Activities: 2015-2024

Historic Cash from Investing Activities for Kura Oncology (KURA) over the last 10 years, with Dec 2024 value amounting to -$101.6 million.

  • Kura Oncology's Cash from Investing Activities rose 106.36% to $94.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$43.5 million, marking a year-over-year change of. This contributed to the annual value of -$101.6 million for FY2024, which is 753.02% down from last year.
  • As of FY2024, Kura Oncology's Cash from Investing Activities stood at -$101.6 million, which was down 753.02% from $15.6 million recorded in FY2023.
  • In the past 5 years, Kura Oncology's Cash from Investing Activities registered a high of $32.6 million during FY2022, and its lowest value of -$126.8 million during FY2021.
  • Over the past 3 years, Kura Oncology's median Cash from Investing Activities value was $15.6 million (recorded in 2023), while the average stood at -$17.8 million.
  • In the last 5 years, Kura Oncology's Cash from Investing Activities surged by 125.72% in 2022 and then slumped by 753.02% in 2024.
  • Kura Oncology's Cash from Investing Activities (Yearly) stood at -$99.9 million in 2020, then fell by 26.92% to -$126.8 million in 2021, then soared by 125.72% to $32.6 million in 2022, then tumbled by 52.32% to $15.6 million in 2023, then tumbled by 753.02% to -$101.6 million in 2024.